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A b s t r a c t  
Hepatocellular carcinoma (HCC) is regarded as one among the deadliest cancers in the world. In 
particular, aflatoxin induced hepatocellular carcinoma is alarmingly on rise due to food 
contamination. However, several drugs and synthetic compound are reported to inhibit HCC in 
humans. Fascaplysin is a marine sponge derived compound has been increasingly considered and 
proved as a potential inhibitor of CDK2/CDK4 dependent kinase. In the present study, five proteins 
that are involved in activation of aflatoxin B1 induced hepatocellular carcinogenesis were selected 
and analyzed for its immunological profiling. Crystal structure of Human Glutathione S-Transferase 
(GST) A1, Prostaglandin H2 Synthase (PHS), Human Cytochrome p450 3A4, Human Microsomal 
P450 1A2 and p53 were assessed for their immunogenicity patterns. On the other hand, HLA B27 
allele which plays a crucial role in cancer was chosen for T cell and B cell epitope mapping. In this 
analysis, it shows that SYFPEITHI immunogenic peptides were conserved in all the proteins 
envisaging the need for a common anti-cancer ligand. However, immunogenic assessment of 
epitopes and interacting residues revealed that fascaplysin interacts at multiple positions in binding 
amino acid residues of the selected proteins. This study is purely based on the immunoinformatics 
approach for the screening of specific compound which could suppress the hepatocellular 
carcinoma. Therefore, based on the results itÊs clear that fascaplysin is a potential inhibitor and 
effectively binds to immunogenic peptides and act as a candidate against aflatoxin induced 
hepatocellular carcinoma based on the Insilco analysis. 
Keywords: Aflatoxin, Hepatocellular carcinoma, Fascaplysin, Immunoinformatics, Epitope mapping. 
Introduction 
Cancer is one among the highly mortal disease that causes death 
worldwide and was estimated to escalate death toll to 12 million in 
2030 [1]. Aflatoxins are toxic secondary metabolites present in 
contaminated foods affecting human health and livestock in tropical 
regions [2, 3]. Aflatoxin B1 (AFB1) produced by Aspergillus flavus 
is toxic to liver and responsible for diseases like toxic hepatitis, 
hemorrhage, edema, immunosuppression and hepatic carcinoma 
[4, 5]. Hepatocellular Carcinoma (HCC) still needs a lot of novel 
abatement procedures and technologies to overcome morbidity 
and mortality. Selective inhibition of cancer cells with reduced 
toxicity to normal cells requires lot of advances. Some interesting 
discoveries viz, anticancer drug encapsulation by delivery system 
[6] monoclonal antibody mediated targeting [7, 8] and cell specific 
peptide ligands against cancerous cells were also reported earlier 
[9, 10]. The activation of aflatoxin has been demonstrated as an 
important step for cytotoxic and genotoxic effects. The metabolism 
of AFB1is activated by cytochrome p450 (CYP450s) enzymes and 
its leads to exo-8, 9 epoxide formations. Especially the cytochrome 
P450 enzymes are mainly involved in the oxidative 
biotransformation of AFB1. Among, several human CYP450 
enzymes CYP1A2 and CYP3A4 are primarily responsible for the 
activation of AFB1 to epoxide formations [11?13]. Immune therapy 
against cancer includes adoptive transfer of ex vivo expanded 
antigen specific T cells and in vivo vaccination [14-17]. Antigen 
presentation is the critical step in immunoinformatics studies and 
provides a significant breakthrough in T cell based cancer 
therapies [18]. The era of immunoinformatics has witnessed 
significant development and applications in the clinical field [19]. In 
silico predictions of T cell epitopes have been successfully applied 
to design new vaccines and autoimmunity studies [20-22]. 
Nevertheless, Major Histocompatibility (MHC) restriction to epitope 
based vaccines design emphasizes the need for immunogenic 
peptide prediction. 
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Fascaplysin derived from the marine sponge Fascaplynopsis sp 
has selectively inhibits CDK4 than CDK2. Molecular insights based 
on thermodynamic integration revealed that Histidine 95 of 
CDK4/CDK2 may play a crucial role in selectivity of inhibition since 
fascaplysin is positively charged. Therefore, maintaining a 
positively charged functional group is important in CDK4 inhibitors 
design [23]. In the present study, five proteins involved in HCC 
were selected namely cytochrome p450 3A4, human microsomal 
p450 1A2 has been mainly present in the wide range of malignant 
tumors especially in HCC [24]. Prostglandlin H2 synthatase is a 
crucial protein for causing human pancreatic adeno carcinoma 
cells [25]. P53 protein is a major oncogenic protein, strongly 
suggesting that downstream effector of large T antigen pathway 
and high level of p53 gene expression is found in all cancer cells 
[26]. GST has been associated with multidrug resistant tumor cells 
and over expression of GSTÊs can increase susceptibility to 
carcinogenesis and inflammatory diseases [27]. The study aimed 
on the fact that epitope based vaccine approach exploits immune 
system functioning and immunoinformatics [28, 29]. The main 
objective of the present study is to development of computational 
approach in developing epitope based vaccinations in arresting a 
HCC. In view of the above, the screening of fascaplysin as a potent 
anti-therapeutic agent against Hepatocellular carcinoma and 
immunogenic profiling of SYFPEITHI prediction of conserved 
immunogenic peptides through T cell and B cell epitope mapping 
was carried out. The immunogenic peptides are then counter 
checked and validated through docking perspectives to evaluate 
the binding efficacies and ligand affinities with fascaplysin 
(Figure1). Nevertheless, aflatoxin induced HCC is least studied on 
the conservancy scale. To the best of our knowledge, HCC 
immunoinformatics precisely has not been studied earlier and this 
report would be first of its kind in addressing this issue. The 
immunoinformatics approach employed in this study will be a 
valuable tool for the generation of hypothesis for the selection of 
biological and immunological targets for experimental analysis. 
This would have high impact in anticancer drug vaccination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic Representation of over all work flow 
 
Materials and Methods  
Protein selection  
Protein structure of significant cancer related proteins were 
retrieved from PDB database (http://www.rcsb.org/pdb/). The 
proteins selected for the analysis were 1PKZ - Crystal structure of 
human Glutathione S Transferase (GST) A1, 1PRH ? 
Prostaglandin H2 Synthase, 1W0E - Crystal structure of human 
Cytochrome p450 3A4, 2HI4 - Crystal Structure of Human 
Microsomal P450 1A2 and 2Z5T- p53. These proteins were 
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significant in aflatoxin induced hepatocellular carcinogenesis. 
Secondary structure prediction of membrane of these five proteins 
is determined by SOSUI server (http://bp.nuap.nagoya-
u.ac.jp/sosui/).  
T cell epitope prediction  
Binding strength of T cell epitope to major histocompatibility 
complex (MHC or HLA) is a significant determinant of 
immunogenicity. Moreover, it allows displaying of higher binding 
affinity T cell epitopes for recognition with T cell receptor [30] For 
identification of immunogenic T cell epitopes, IEDB was used for 
assessing MHC class I and class II epitopes 
(http://tools.immuneepitope.org/analyze/html/mhc_binding.html). 
IEDB involves utilization of ANN algorithm utilizing Stabilized Matrix 
Method (SMM). Non overlapping epitopes were selected as 
possible and potent epitopes [31].  
B cell epitope prediction  
B cell epitope prediction by BCPRED 
(http://ailab.cs.iastate.edu/bcpreds/predict.html) was performed on 
the basis of ex vivo analysis. Epitopia server 
(http://epitopia.tau.ac.il/) incorporates a machine learning based 
algorithm for predicting immunogenic B cell epitopes. Conserved B 
cell epitopes were selected as conformational epitopes. 
Accessibility prediction  
Accessibility involves disparity between solvent accessible surface 
area and the area for immunogenicity on the protein surfaces. The 
solvent accessible surface area was analyzed employing Kyte and 
Doolittle method GETAREA (http://curie.utmb.edu/getarea.html).  
Prediction of minor histocompatibility antigens (or) 
mHagÊs prediction  
Minor histocompatibility antigen predictions are significant in 
analyzing mutational parameters and variations in single nucleotide 
polymorphism that contribute to carcinogenesis. mHagÊs are 
peptides presented by MHC that is responsible for alloreactive 
immune response. Sipep (http://igrid-
ext.cryst.bbk.ac.uk/snp/pro.php) which utilize coding non 
synonymous SNPs mutation with data form dbMHC and Hap Map 
projects was used in the present study. The methodology 
described here employs SYFPEITHI mode of HLA binding [18].  
Preparation of ligands  
The ligand chosen was retrieved from the PUBCHEM data base 
(http://pubchem.ncbi.nlm.nih.gov/) and the 3D structures were 
generated using arguslab. RMSD based energy minimization was 
performed in vacou to give a first optimization of the rough 
structure using VEGA ZZ [32]. Hydrogen was initially added to 
receptor molecule, AMBER and gasteiger charges were added to 
fix unusual bonds in the 3D structure which utilizes CHARMM force 
field parameters.  
Interaction Assessment  
Patch dock was used for interaction assessment with a default 
value RMSD 4.0. Patch dock is a molecular docking algorithm 
based on shape complementarity principle. The highest scores 
were taken as significant interaction with less atomic contact 
energy (ACE). Hydrogen bond interactions were assessed by 
MOLEGRO (http://www.molegro.com/). The active site binding to 
fascaplysin was assessed by Leadit functions of FLEXX docking 
with flexible residues (http://www.biosolveit.de/FlexX/).  
Result and Discussion  
T cell epitope prediction  
In this study, epitope mapping is restricted to HLA B27 as the 
association might share a pathogenic pathway in aflatoxin induced 
HCC [33]. The atomic SASA covered by each cleft was calculated 
by utilizing radius of water probe 1.4 Ao and the area/energy per 
residue was calculated. When the protein surface was exposed for 
major solvent accessible surface area it reflects in the hindering of 
immunogenic response in in vivo. The Area/ Energy per residue 
were calculated which indicates the higher energy for prostaglandin 
H2 synthase (40911.93) than other proteins. The result confirmed 
the fact that accessible surface area increases the immunogenicity. 
The SASA result for glutathione S- transferase shows it is an  
apolar rich residue that made us unable to calculate area/energy 
per residue. Our results clearly indicated that the higher solvent 
accessible surface area leads to higher level of immunogenicity 
and SASA results tabulated in (Table 1a) also confirm the same. 
Immunogenic peptides for identification of vaccines candidate by 
employing traditional molecular immunology techniques were 
expensive and time consuming [34]. However, bacterial 
recombinant attenuated vaccines are potent and safe in developing 
immune strategy. 
 
 
Table 1a. Solvent accessible surface area (SASA) 
S.No Proteins name Area/Energy Per 
Residue 
1 Cytochrome P450 1A2 20928.46
2 glutathione S transferase (GST) 
A1 
-nan*
 
3 Cytochrome P450 3A4 19450.28
4 prostaglandinH2synthase 40911.93
5 P53 16311.47
-nan* denotes apolar rich residues that renders GST with no 
solvent accessibility 
 
On the other hand, emerging immunoinformatics has led to 
increased discovery of cancer immune therapies [35]. Based on 
the analysis among five proteins, cytochrome p450 1A2 is a 
transmembrane protein and the remaining were soluble proteins. 
The flexibility, hydrophilicity, polarity and surface properties at a 
threshold value of 2.38 were employed for accurate prediction. The 
analysis of T cell epitope mapping showed highly conserved region 
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of R (Arginine) in the second position of predicted MHC I binding 
region. Based on IC50 values, prostaglandin H2 synthase and 
glutathione S-transferase A1 showed best binding affinity at 0.10 
nM than the other proteins (Table 1b). The analysis of the varied 
nature of binding characteristics the chosen proteins with MHC II 
molecules clearly depicts in Table 1c. Binding affinities of T cell 
epitopes predicted may be due to the phenomenon of enthalpy-
entropy compensation [36]. T cell epitope mapping provided a 
rough map of MHC I and MHC II binding peptides. The peptides 
identified were not conserved and hence B cell epitope prediction 
was sought.  
 
Table 1b. MHC ?I binding Prediction based on artificial neural network and simplified matrix methods. 
S.No Proteins Name  Allele Start End Peptide 
Length  
Sequence IC 50 
value in 
nM 
1 Cytochrome P450 1A2 HLA-
B*27:05 
113 122 10 RRLAQNALNT 0.20 
2 Glutathione S transferase (GST) 
A1 
HLA-
B*27:05 
14 23 10 GRMESTRWLL 0.10 
3 Cytochrome P450 3A4 HLA-
B*27:05 
423 432 10 MRFALMNMKL 0.15 
4 prostaglandinH2synthase HLA-
B*27:05 
147 156 10 RRFLLRRKFI 0.10 
5 P53 HLA-
B*27:05 
100 109 10 KRNLVILNNS 3.00 
 
 
Table 1c. MHC ?II binding Prediction based on NetMHC pan II. 
S.No Proteins Name  Allele Start End Sequence IC 50 value in nM
1 Cytochrome P450 1A2 HLA-
B*27:05 
214 228 FFPILRYLPNPALQR 0.27 
2 Glutathione S-Transferase (GST) A1 HLA-
B*27:05 
177 191 SFPLLKALKTRISNL 0.53 
3 Cytochrome P450 3A4 HLA-
B*27:05 
367 381 PKGVVVMIPSYALHR 0.31 
4 Prostaglandin H2 Synthase HLA-
B*27:05 
256 270 GQEVFGLLPGLMLYA 0.09 
5 P53 HLA-
B*27:05 
100 114 KRNLVILNNSDAAKN 0.92 
 
B cell epitope prediction  
The B cell epitopes showed varied and diversed presence of amino 
acid indicate its cell type. The Immunogenic residues were 
recognized employing SYFPEITHI predictions. The epitopes were 
found within the range of 23 ? 31 epitopes with highest 
corresponding to prostaglandin H2 synthase with 31 epitopes and 
least for p53. Low number of epitopes for p53 is due to the fact that 
it is a tumor suppressor protein. SYFPEITHI predictions reveal that 
R (Arginine) in the second position and F (Phenylalanine) and L 
(Leucine) are highly conserved among all the proteins involved in 
HCC was reported in Table 2a. 
 
 
Table 2a. SYFPEITHI Predictions of Immunogenicity 
S.No Proteins Name  Position Epitope No. of epitopes
1 Cytochrome P450 1A2 54 I R I G S T P V L 28 
2 Glutathione S transferase (GST) A1 14 G R M E S T R W L 25 
3 Cytochrome P450 3A4 83 R R P F G P V G F 27 
4 Prostaglandin H2 synthase 147 R R F L L R R K F 31 
5 P53 26 P R A P L L Q I L 23 
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Interestingly, in both T cell and B cell prediction the R (Arginine) in 
the second position is highly conserved it might be significant for 
immunogenic nature. The role of R (arginine) and L (Leucine) 
present in the binding pockets are specially indicated for ligand 
binding. The role of two residues are counter balanced in the 
binding packets depending on the chemical structure of ligand in 
which it gives flexibility to the binding pocket and allow binding to 
ligand [39]. In the present study, fascaplysin is a ligand and also R 
(arginine) and L (Leucine) are present in the binding pocket of the 
target protein, therefore it might play a crucial role in the ligand 
binding. Furthermore, profiling of predicted epitopes that are 
responsive to proteosomal cleavage was performed by minor 
histocompatibility antigen prediction. Proteosomal cleavage 
assessment relies on the fact that a complex pathway was involved 
in proteolysis [37, 38].  
Prediction of minor histocompatibility antigens (or) 
mHagÊs prediction  
Predicted antigenic peptides that can bind to minor 
histocompatibility antigens were conserved with R (arginine) in the 
second position and L (Leucine) in the ninth position. However, 
proteasomal cleavage was absent in cytochrome p450 1A2 an 
ample proteosomal cleavage depicts the mHagÊs based on SNPÊs 
in Table 2b. CombiPred and NHLAPred defines the proteosomal 
cleavage and it holds good for all the proteins except for 
cytochrome p450 1A2. This might be correlated with peptide 
position as 527th position is so far from the start site. In general, T-
cell epitope are protein fragments present in the cell surface which 
trigger immune system to detect and respond immediately, 
however in the present study the fascaplysin prefer both T and B 
cell epitope binding regions of cytochrome p450 1A2 protein. 
Further, the chosen proteins were subjected to docking to assess 
the inhibitory nature of the drug.  
 
Table 2b. Prediction of minor histocompatibility antigens (or) mHagÊs prediction 
 
S.No Proteins Name  
Position Peptide 
Proteasomal 
Cleavage 
CombiPred NHLAPred 
1 Cytochrome P450 1A2 527 RRFSINHHH 0 5.8 -2.65 
2 Glutathione S transferase (GST) 
A1 
43      GRMESTRWL 6.3 4. 08 -5.35
3 Cytochrome P450 3A4 138 LRSLLSPTF 6.59 4.76 -4.28 
4 Prostaglandin H2 synthase 444 GRNIDHHIL 6.24 5.06 -3.82 
5 P53 83 GQYIMMKQL 6.44 2.99 -7.06 
 
Interaction Assessment  
The interaction study was performed by rigid protein target and 
flexible ligand. The selected target proteins were predicted for its 
immunogenic regions. The immunogenic residues found in the 
epitopes predicted were inspected manually and found p53 had no 
efficient binding assessed by the least score of interaction and all 
other proteins were found to possess the immunogenic residues in 
the binding site of the docked complex. The lower binding scores 
and increased ambiguity renders the docked complex as highly 
stable. Figure 2 shows the 3D models of selected proteins and 
ligand. Based on the docking study cytochrome p450 1A2 had the 
highest binding and ambiguity score for the fascaplysin was 
tabulated in table 3. Figure 3, indicates the interaction studies in 
the displacement of water and its role in the stable interaction. 
Cytochrome p450 3A4 had water displaced at Cys 422 and Gly 
444 positions interestingly Phe, Gly, Val and Ile were dominated in 
the binding region. GST had Ser at 18th position in the water 
displacement site majority of interacting residues belongs to Thr, 
Ser, Gly, Arg, Glu and Leu. On the other hand, cytochrome p450 
1A2 displaced the water molecule and shows interaction with Leu 
450, Gln 411 and also interact with other amino acids present in 
the active site (Gly, Thr and Leu). Similarly, prostaglandin H2 
synthase had His 207 and Gln 289 in the displaced portion with 
Phe and Lys in the realm of interaction. All the proteins chosen had 
a positive interaction, except for p53 which is a tumor suppressor 
protein. While analyzing the protein and ligand interaction the 
conserved amino acids R (Arginine) found at the interacting site 
based on the T cell and B cell interaction and correlation with 
interactions studies it clears that Arginine and Lysine might play a 
key role in interaction of protein and fascaplysin to inhibit HCC. 
Sorafenib, an inhibitor targeting vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF) and Raf signaling 
pathways is the only available drug prolonging survival of HCC 
patients [40 - 41]. Manual inspection of the immunogenic peptides 
profiles among the interacting residues. Docking perspectives of 
fascaplysin reveals that it inhibits HCC, as the immunogenic 
peptides are majorly involved in binding pockets of the docked 
complexes.  
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Figure 2: Proteins and ligand used in the analysis A) Crystal Structure of Human Microsomal P450 1A2, B) Crystal structure of human 
Glutathione S-Transferase (GST) A1, C) Crystal structure of human Cytochrome p450 3A4, D) Prostaglandin H2 Synthase , E) p53 and F) 
Fascaplysin. 
 
Table 3. Flexx score and Binding energy of Docked complexes   
S.No Proteins Name  Score Ambiguity 
1 Cytochrome P450 1A2 -29.0422 -5.8292 
2 Glutathione S transferase (GST) A1 -22.2598 -5.7603 
3 Cytochrome P450 3A4 -21.3188 -4.5851 
4 Prostaglandin H2 synthase -20.3068 -6.5846 
5 P53 -16.5255 -4.0533 
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Figure 3: Docked complexes of the five proteins with fascaplysin showing potent interactions with displaced water residues. 
Conclusion  
Immunoinformatics serves as a valuable tool to screen and select 
antigenic peptides as a potential T cell and B cell epitope for 
finding affinity with these selected target proteins. Fascaplysin is an 
efficient abatement tool to combat HCC. Immunogenic profiling 
revealed that epitopes specific for eliciting an immune response. In 
this study the cytochrome p450 1A2 had higher binding to 
fascaplysin with this interaction result it might be the right pathway 
to inhibit the AFB1 induced HCC. Lessened toxicity of fascaplysin 
was assessed by the earlier report suggested that up to 10 mg/kg, 
of fascaplysin was not toxic to mice [42]. Our results were also 
consistent with the above report suggesting that fascaplysin was 
less toxic. The approach employed in the present study will be a  
 
 
valuable tool for the generation of scientific hypothesis in the 
selection of biological and immunological targets for experimental 
testing. This analysis could be extended for all cancers and design 
of novel DNA vaccines based on immunogenic profiling.  
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